Our Faculty
Sebastián Malleza, M.D.
Publications of Sebastián Malleza, M.D.
Side Effects of Antidepressants Part 5 (Hyperprolactinemia)
No Credits
Antidepressant-Induced Excessive Sweating
No Credits
Tricyclic Antidepressants in Psychiatry
No Credits
Gastrointestinal Side Effects of Antidepressants: Mechanisms, Comparison and Management Strategies
0.50 CMEs
Buspirone Guide: Pharmacology, Indications, Dosing Guidelines and Adverse Effects
0.50 CMEs
This guide provides a comprehensive overview of buspirone, a 5-HT1A partial agonist approved for generalized anxiety disorder, covering its non-GABAergic mechanism, pharmacokinetics, significant CYP3A4 drug interactions, dosing strategies, side effects, various special population considerations, and clinical positioning as a non-sedating anxiolytic without significant dependence risk.
Trazodone Guide: Pharmacology, Indications, Dosing Guidelines and Adverse Effects
0.50 CMEs
This guide provides a comprehensive review of trazodone, a serotonin antagonist and reuptake inhibitor (SARI) FDA-approved for depression but predominantly prescribed off-label for insomnia, covering its dose-dependent pharmacology, clinical uses, drug interactions, side effects including priapism and QT prolongation, and special population considerations.
2025 in Review: FDA Approvals, Practice Guidelines, and Label Changes in Psychiatry
0.50 CMEs
This guide provides a comprehensive overview of 2025's key regulatory and guideline updates in psychiatry, covering new FDA approvals, label changes, and practice guidelines across depression, schizophrenia, addiction, neurocognitive disorders, and neurodevelopmental conditions, emphasizing practical implementation considerations for clinicians.
Serotonin Syndrome: Mechanisms, Diagnosis, High-Risk Interactions, and Management
1.00 CMEs
This guide provides a comprehensive review of serotonin syndrome, covering its pathophysiology, clinical presentation using Hunter Criteria, risk stratification of drug combinations, and severity-based management strategies including supportive care and cyproheptadine use.
Antidepressants and Metabolic Disturbances
0.50 CMEs
This guide examines antidepressant-induced weight gain mechanisms, risk stratification of medications (highest risk: mirtazapine, paroxetine, TCAs; lowest: bupropion, fluoxetine, vortioxetine), patient vulnerability factors, monitoring protocols, and management strategies including medication switching and adjunctive treatments.
Vilazodone: Pharmacology, Indications, Dosing Guidelines and Adverse Effects
0.50 CMEs
This guide provides a comprehensive overview of vilazodone, a dual-action SSRI with 5-HT1A partial agonist properties approved for major depressive disorder, detailing its pharmacology, clinical applications, dosing requirements with food, drug interactions, side effects, and positioning relative to standard antidepressants despite lacking proven superiority.
Initial Antidepressant Selection for Unipolar Depression: Translating Guidelines into Practice
0.50 CMEs
This guide presents a contemporary framework for selecting initial antidepressant therapy in Major Depressive Disorder, emphasizing personalized treatment matching based on symptom clusters, patient priorities, and comorbidities through shared decision-making and measurement-based care approaches.
Antidepressant-Induced Emotional Blunting: Diagnosis, Mechanisms and Management
0.50 CMEs
This guide explores antidepressant-induced emotional blunting (AIEB), a common side effect affecting 40-60% of patients on SSRIs/SNRIs. It covers clinical recognition, differentiation from depression, underlying serotonin-dopamine mechanisms, risk stratification across antidepressant classes, and evidence-based management strategies including dose reduction and switching options.
1